Table of Contents
USE OF PROCEEDS
We estimate that our net proceeds from this offering will be approximately $54.2 million, assuming an initial public offering
price of $13.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. If the underwriters exercise their option to purchase additional shares in full, we estimate that our net proceeds from this offering will be approximately
Each $1.00 increase or decrease in the assumed initial public offering price of $13.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus,
would result in an approximately $4.4 million increase or decrease in our net proceeds from this offering, assuming that the number of shares offered by us, as set forth on the cover page of
this prospectus, remains the
same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase or decrease of one million shares in the number of shares to
be offered by us would increase or decrease our net proceeds from this offering by approximately $12.1 million, assuming that the public offering price is $13.00 per share, the midpoint of the
price range set forth on the cover page of this prospectus and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.
expect to use the net proceeds of this offering as follows:
- approximately $9.4 million to accelerate the commencement of the second of our Phase 3 trials for PRT-201 in
its lead indication;
- approximately $28.4 million to accelerate our chemistry and manufacturing controls, or CMC, activities;
- approximately $1.6 million to fund additional research and development activities; and
- the remainder for working capital and general corporate purposes and the costs associated with being a public company.
We believe that the net proceeds from the offering, together with our existing cash and cash equivalents and investments, will be sufficient to fund our projected operating expenses and
capital expenditure requirements through the end of 2017, allowing us to obtain results from our first Phase 3 clinical trial of PRT-201 in radiocephalic AVFs and complete our anticipated
chemistry, manufacturing and controls activities required for a BLA submission. However, this may change if there are any significant increases beyond our expectations in spending on development
programs or more rapid progress of development programs than anticipated. We do not expect the proceeds to be sufficient to obtain the results from our second Phase 3 trial.
expected use of net proceeds from this offering represents our intentions based upon our present plans and business conditions, which could change in the future as our plans and
business conditions evolve. The amount and timing of our actual expenditures will depend upon numerous factors, including the results of our ongoing clinical trials and clinical trials that we may
commence, feedback from regulatory agencies, the timing of approval of any of our product candidates, the results of any commercialization efforts and other factors. As a result, our management will
have broad discretion over the use of the net proceeds from this offering.
the use of the proceeds from this offering, we intend to invest the net proceeds in short-term, interest-bearing, investment-grade securities, certificates of deposit or
We have never declared or paid any cash dividends on our common stock. We currently intend to retain all of our future earnings, if
any, to finance the growth and development of our business. We do not intend to pay cash dividends to holders of our common stock in the foreseeable future.